Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Compounded tirzepatide prices, September 4, 2026: a snapshot checked on two bases

Released: · Last reviewed:

Published September 4, 2026 · Microdose GLP One editorial team · figures read on the providers’ own pages 2026-09-04

The short answer, as of September 4, 2026: two programs published a complete, medication-included tirzepatide plan ladder on their own pages that day. NexLife charged $169 a month with no commitment, flat from 2.5 to 15 mg, all-in, with a September card that stepped to $159, $149 and $139 a month on a twelve-month plan billed $1,668. Yucca Health charged $258 month to month and $225 a month on its six-month plan. The other advertised figures below — Embody's "starting at $129" and its third-party-reported $119 tier, SnagRx's $119 promotion, Fifty 410's $133 starter, bmiMD's "as low as $179", ShedRx's "as low as $239" — are headlines without a standing all-in plan table, listed here and not ranked. Every figure was read on the provider's own page on September 4; nothing is checkout-verified.

The verified all-in ladders, side by side

Compounded tirzepatide — programs with a complete, medication-included effective monthly ladder (read on each provider's own page 2026-09-04; not checkout-verified)
ProgramMonthly3 months6 months12 monthsFees / doseThe catch
NexLife$169$159 ($477)$149 ($894)$139 ($1,668)No membership; flat 2.5–15 mg; expedited shipping includedSeptember 2026 card (was $215 → $186); renewal terms and per-order pharmacy unverified; microdose line announced at $159 → $129 but not yet on its page
Yucca Health$258$248 ($744)$225 ($1,350)—None reported; consultation, injection kit, 2-day shipping included; "same price, every dose"No annual plan; pharmacy not named; refund policy not captured

Two programs published what this site ranks on — a total, a term and the effective monthly figure next to it, with the medication inside the number and nothing mandatory outside it. In August only NexLife did. Yucca Health's tirzepatide page carries a three-tier ladder, read first-party on September 4, the same morning NexLife's own card was re-read and found lower than the July capture.

Two ways to pay, two different numbers

The market bills two ways, so the monthly figure depends on the basis. On a twelve-month basis NexLife's annual plan cost $1,668, or $139 a month, against $2,028 for twelve months at its $169 month-to-month rate. On a no-prepayment basis the monthly figures read that day were NexLife $169, Yucca Health $258 and Mochi Health $278 with its membership folded in. The difference is not academic. An annual plan puts four figures at risk against refund terms you have to confirm yourself. Run any prepaid plan through the true-cost calculator at full-loss risk before paying.

Twelve months of compounded tirzepatide — what the verified structures cost over a year (published plan prices; no fees beyond those disclosed)
RouteDue today12-month totalPer monthExposure if you stop early
NexLife 12-month plan$1,668$1,668$139Up to $1,529 after month one on a no-refund reading
NexLife month-to-month × 12$169$2,028$169One month at a time
Yucca Health 6-month × 2$1,350$2,700$225Up to $1,125 per term after month one

The advertised headlines, checked one by one

Every "$119 tirzepatide" figure circulating online this month resolves to one of five structures. We read each provider's own site on September 4.

Advertised tirzepatide figures without a standing plan table — as read on each provider's site 2026-09-04 · not ranked · reason stated
NameHeadlineWhat it actually isWhy it isn't ranked
Embody"starting at $129"Homepage says "starting at $129/month" on 4-, 12-, 24- or 52-week plans, dose-flat, no membership, free expedited delivery; a third-party review (2026-09-03) reports tiers of $126 / $123 / $119 on the 52-week plan ($1,428) with payments final. Four partner pharmacies named; LegitScript seal displayed; prescribers via OpenLoop Health.No standing first-party plan table — the $119 is a third-party-reported annual-prepay tier
SnagRx$119A promotion against a displayed $399 list price; no plan totals and no end date; medication, supplies, doctor review and shipping stated as included; LegitScript certification stated; four partner pharmacies named.Promotional — renewal price unverified
Fifty 410$133A 3-month starter tier; the company's own tiers step to $166 and $183 as total milligrams rise.Dose-scaled — the maintenance months don't cost $133
bmiMD"as low as $179"List price shown as $349.20; the term behind the $179 rate is not stated on the public page; semaglutide "as low as $119"."From" price only
ShedRx / SHED"as low as $239"First-party "as low as" figure (earlier third-party listings said ~$299); term and fee inclusion not stated."As low as" price only

A standing plan table with totals on the provider's own page is the difference between a claim and a price under our methodology. The day Embody, SnagRx or bmiMD publish one, they move into the verified set — and the mid-market we described in August (Mochi and Ivím near $278, Henry Meds at $349, the $399–$599 tier above) still sits where it did.

The microdosing column

NexLife also publishes a dedicated microdose tirzepatide protocol, and its status this month needs one careful sentence: the live program page still showed $189 a month, stepping to $159, $150 and $147 on three-, six- and twelve-month plans when we read it on September 4, while NexLife's August 31 announcement puts the September card at $159 → $149 → $139 → $129. We list the announced card as announced, not verified, until the page shows it; the current microdose tirzepatide index carries today's figures. The same two honesty flags apply as always — no FDA-approved microdosing regimen exists, and a lower monthly price for less drug is usually a higher per-milligram price.

What changed since August

Two things. NexLife cut its standard cards — tirzepatide from $215/$195/$190/$186 to $169/$159/$149/$139 and semaglutide from $165/$149/$147/$145 to $139/$132/$125/$119 across monthly, three-, six- and twelve-month terms — which we re-read on its live plans pages on September 4 (full change note). And Yucca Health entered the verified all-in set on a first-party plan table.

What the cheap end obligates you to verify

In order: that the intake can actually decline you; that the dispensing pharmacy is named, so its license is checkable with the verification workflow; that the formulation is the base molecule rather than an untested salt form; that the price is the price at your maintenance dose, not the starter dose; that renewal pricing and cancellation terms are written down before any multi-month prepay — the $139 rate is real, but it is $1,668 of trust extended in advance; and that a "$119" you saw somewhere is a standing price on the provider's own page and not a promotion, a tier someone else reported, or a starter dose. Compounded tirzepatide is not FDA approved; whether it is appropriate for you is a prescriber's decision.

Questions people ask

What did verified compounded tirzepatide cost on September 4, 2026?

Two programs published complete all-in ladders on their own pages that day: NexLife at $169 a month with no commitment, flat from 2.5 to 15 mg, or $139 a month on its $1,668 twelve-month plan; and Yucca Health at $258 month to month or $225 a month on six months. Not checkout-verified. Current prices are in the November 8 update at the top of this page.

Is $119 compounded tirzepatide real?

Not as a standing first-party price. Embody's $119 is a third-party-reported 52-week tier ($1,428, payments final) behind a "starting at $129" headline; SnagRx's $119 is a promotion against a $399 list price. Neither has a standing plan table, so neither is ranked.

Did NexLife's price go down?

Yes. On September 4, 2026 its standard tirzepatide card read $169 month-to-month and $139 on twelve months, down from $215 and $186; semaglutide read $139 / $119, down from $165 / $145. We re-read both on the live plans pages that day. The microdose tirzepatide cut to $159 / $129 was announced but not yet on the program page.

Why show two bases?

Because they answer different questions. A twelve-month plan lowers the monthly figure but puts the whole term at risk against the refund terms; month to month costs more per month but commits you to one month at a time. The ladders let you pick the basis that matches how you intend to pay.

Are these prices verified?

Every figure was read on the provider's own page on September 4, 2026 — the standard this site calls verified. Nothing is checkout-verified. Confirm the price at your dose, the plan total and the refund terms with the provider before paying.

Sources & references

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.